1. In Vivo
  2. >>Business Strategy

Sigma Aldrich Bows out of Diagnostics

Sigma Aldrich's decision to abruptly exit the clinical diagnostics business is a cautionary tale for both large companies seeking to enter diagnostics and for small companies looking for deep-pocketed saviors. In April, after selling a small immunoassay business to Ivax Diagnostics, Sigma laid off nearly all of its diagnostics division's 600 employees, effectively all but shutting down the business. Under pressure from Wall Street, it decided to cut its losses rather than sell an on-going concern.

Sigma Aldrich Corp. 's decision to exit diagnostics abruptly is a cautionary tale for large health-care companies who see diagnostics as a comparatively "easy" play that compliments their non-diagnostic core businesses, and a lesson for at least one small firm that thought it had landed a deep-pocketed savior. In April, after selling a small immunoassay product line to Ivax Diagnostics Inc. [See Deal], the life sciences company all but shut down most of its $77 million in revenues diagnostics business, laying off nearly 600 employees. Sigma continues to maintain a minimal staff to service existing customers, but has put remaining assets, including factories and inventory, up for sale.

The saga started about two years ago, when Sigma Aldrich decided to expand its small reagent diagnostics business and refocus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By Ashley Yeo

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.